Janssens STELARAÂ ustekinumab Demonstrates Sustained Efficacy in Improving Clinical Remission Rates in Patients with Moderate to Severe Crohns Disease Throughout Three Years

New study data also confirm efficacy for STELARAÂ ustekinumab in patients who are nave and refractoryintolerant to tumour necrosis factor TNF antagonist treatment The Janssen Pharmaceutical Companies of Johnson & ...